Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and genOway, a leader in conceiving and developing genetically engineered preclinical research models, today announced a non-exclusive licence agreement granting genOway past and future access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
ERS Genomics and genOway enter CRISPR/Cas9 agreement
“CRISPR/Cas9 is a powerful in vivo genome engineering tool that has revolutionised many research areas. At ERS, we are committed to make this technology broadly available. We are very pleased to support genOway’s development with this licence agreement,” said Eric Rhodes, CEO of ERS Genomics (pictured).
“This licence from ERS will broaden our CRISPR IP portfolio, and widen our rodent models offering,” said Alexandre Fraichard, CEO of genOway. “This will ultimately enable us to pursue our mission of providing the scientific community with scientifically highly relevant preclinical models paired with guaranteed freedom to operate, in particular for commercial applications.”
Financial details of the agreement are not disclosed.
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.